Stoke Therapeutics, Inc. Cash and Restricted Cash
Stoke Therapeutics, Inc. (STOK) had Cash and Restricted Cash of $233.25 million as of 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2019-11-12
- 2019-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $233.25M.
- 2019-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $242.88M.
- 2018-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $19.42M.
- 2018-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.60M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2019-09-30 | $233.25M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $242.88M 10-Q · filed 2019-08-14 |
| 2018-09-30 | $19.42M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $9.60M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |